• Product NameEpalrestat
• Brief DescriptionInhibitors
• Purification98.00%
• Biological ActivityEpalrestat is an aldose reductase inhibitor. Long-term treatment with epalrestat is well tolerated and can effectively delay the progression of diabetic neuropathy and ameliorate the associated symptoms of the disease, particularly in subjects with good glycemic control and limited microangiopathy.
• Target NameReductase inhibitor
• CAS No. 82159-09-9
• Calculated MW 319.39
• Formulation C15H13NO3S2
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Nervous system
  SMILES:C/C(=C\C1=CC=CC=C1)/C=C\2/C(=O)N(C(=S)S2)CC(=O)O
  Pathways:Endocrinology/Hormones; Enzyme
  Receptor:Aldose reductase
  Boling pt:
  Melting pt:210-217 C
  Solubility:DMSO: 2 mg/mL (6.26 mM)
  Appearance:Orange Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Ramirez MA, et al. PharmacOthersapy. 2008 May; 28(5):646-55.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting